Investor's Business Daily on MSN
Dow Jones futures: Stocks rise on Micron, inflation, but don't do this; Nike, Fed earnings late
Dow Jones futures edged higher early Friday, along with S&P 500 futures and Nasdaq futures. FedEx[ticker symb=FDX] and ...
Eli Lilly stock hits a 90+ Quality score. BofA calls LLY underpriced, citing major growth ahead for its oral obesity drug.
1don MSNOpinion
CPI inflation data rocks stocks
Goldilocks. That’s probably the best way to describe it. Investors, including me, were fearing the worst: a Fed hamstrung by ...
3don MSN
Is Eli Lilly a Buy Before 2026?
Eli Lilly ( LLY 2.00%) recently announced stellar results from a phase 3 clinical trial, Triumph-4, which evaluated efficacy ...
The world is moving fast, and unexpected events can spill over into the economy and markets, ultimately hitting consumer and business confidence, and influencing spending and investment decisions on ...
Forbes contributors publish independent expert analyses and insights. Peter Cohan, a Boston-based senior contributor, covers stocks. Eli Lilly achieved a $1 trillion market cap, a healthcare first, ...
The pharmaceutical leader has established itself as the leader in the fast-growing weight loss market. And although many other drugmakers are hot on its tail, Lilly has consistently demonstrated that, ...
Bank of America sees Eli Lilly's obesity drug growth underestimated, forecasting $3 billion Orfoglipron revenue by 2026 as ...
Pharmaceutical Technology on MSN
Eli Lilly picks Alabama as home to $6bn orforglipron manufacturing facility
The Alabama facility is part of the $27bn investment Eli Lilly has pledged to expand its US footprint. American ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback